Glaucoma Research Foundation (GRF) today announced a total of $1.3 million in annual research grants to support 10 investigators at prominent universities across the United States.
Glaucoma Research Foundation, the nation’s most experienced foundation dedicated solely to glaucoma research and education, recently elected Oluwatosin “Tosin” Smith, MD to its Board of Directors.
Glaucoma Research Foundation (GRF) will host the 11th Annual Glaucoma 360 New Horizons Forum on February 11th at the Grand Hyatt Union Square in San Francisco. Offered both in person and virtually, this important meeting brings together leaders in glaucoma research and industry to speed the translation of new ideas to improved treatments for glaucoma patients.
Ronald L. Fellman, MD, David Calkins, PhD, and Steven and Michele Kirsch will be honored at the Glaucoma Research Foundation's Annual Gala on February 10, 2022.
David Calkins, PhD, a leading authority on the neurobiological basis of vision loss in blinding eye disease, will be honored at the Glaucoma 360 Annual Gala on February 10, 2022.
Can mindfulness meditation help patients with glaucoma? A recent study suggests that there may be benefits to eye pressure and optic nerve health by doing meditation on a regular basis.
January, National Glaucoma Awareness Month, is an excellent time to get a comprehensive dilated eye exam—the most effective way to test for glaucoma—and to convince your loved ones to get tested, too.
January, National Glaucoma Awareness Month, is an excellent time to focus on eye health.
Understanding how your IOP (intraocular pressure) changes over time can help you and your doctor feel confident that your glaucoma treatment is working effectively.
The 4-star rating is Charity Navigator's highest rating, indicating that Glaucoma Research Foundation exceeds industry standards and outperforms most charities in its cause.
The Kirsch gift will be a matching opportunity to inspire other donors to support this groundbreaking research to restore vision lost due to glaucoma.
Glaucoma Research Foundation (GRF) today announced a total of $1.7 million in annual research grants to support 13 investigators at prestigious colleges and universities across the United States.
For his research project studying neuroprotection in glaucoma, Pete Williams, PhD from the Karolinska Institutet in Stockholm was awarded the 2021 Shaffer Prize for Innovative Glaucoma Research.
The Catalyst Award will be presented to Ramin Valian of Allergan, an AbbVie Company, in recognition of Allergan's ongoing leadership and commitment to the development of innovative treatments to advance glaucoma care.
The COVID-19 pandemic has presented many challenges including delayed eye doctor appointments. This video will discuss changes eye doctors have made to improve safety during every step of the office visit.
National survey finds appointment delays and cancellations were the greatest cause of concern; waiting for in-person appointments is greatly preferred over telemedicine.
The 4-star rating is Charity Navigator's highest possible rating and indicates that Glaucoma Research Foundation adheres to sector best practices and executes its mission in a financially efficient way.
The glaucoma specialist and researcher from Glaucoma Center of San Francisco is also a medical editor for the Gleams newsletter published by Glaucoma Research Foundation and lecturer at the annual Glaucoma 360 Symposium in San Francisco.
The annual Glaucoma 360 Gala at the Grand Hyatt San Francisco honored leaders in glaucoma research innovation and visionary glaucoma advocates helping to raise awareness.
GRF annual glaucoma research grants will support 12 investigators at prestigious colleges and universities across the United States.
The Shaffer Prize recognizes a researcher whose project best exemplifies the pursuit of innovative ideas in the quest to better understand and cure glaucoma.
The three-day event highlights innovation in glaucoma therapies to ensure patients have access to the latest and most effective diagnostic tools and treatment options.
Ophthalmology industry innovators Vicente Anido, Jr., PhD and Thomas A. Mitro of Aerie Pharmaceuticals, Inc. will be honored at the Glaucoma 360 Annual Gala on February 6, 2020 in San Francisco.
Preliminary applications for one-year Shaffer Grants in the amount of $50,000 are being accepted until July 15, 2019 through the Glaucoma Research Foundation website.
Nancy and Pat Forster chaired Glaucoma Research Foundation’s 2019 Annual Glaucoma 360 Gala, raising a record $660,000 to advance glaucoma research and education programs.
The Catalyst for a Cure Vision Restoration Initiative builds on 16 years of seminal scientific research, with an aim to cure glaucoma and restore vision.
The announcement during World Glaucoma Week emphasizes the need to find a cure for this disease that affects more than 60 million people worldwide.
For her research project seeking a new treatment to restore vision in glaucoma patients, Adriana Di Polo, PhD, professor of neuroscience at the University of Montreal, was awarded the 2019 Shaffer Prize for Innovative Glaucoma Research. The 2019 Shaffer Prize was presented on January 31st during ceremonies at the Glaucoma 360 Annual Gala at the Palace Hotel in San Francisco.
Glaucoma is a group of eye diseases that gradually steal sight without warning. Although the most common forms primarily affect the middle-aged and the elderly, glaucoma can affect people of all ages.
Three days of events uniting research, industry, and philanthropy to prevent vision loss from glaucoma and speed the cure.
Launched in 2007, this annual benefit showcases the visionaries and catalysts who share Glaucoma Research Foundation's mission to cure glaucoma and restore vision through innovative research.
What is Normal-tension glaucoma? Also called low-tension or normal-pressure glaucoma, normal-tension glaucoma (NTG) is a condition in which the optic nerve is damaged without eye pressure exceeding the average range (usually between 12-21mm Hg).
What is Normal-tension glaucoma? Also called low-tension or normal-pressure glaucoma, normal-tension glaucoma (NTG) is a condition in which the optic nerve is damaged without eye pressure exceeding the average range (usually between 12-21mm Hg).
Currently, all therapy for glaucoma is directed at lowering eye pressure, but the fundamental problem in glaucoma is the degeneration of the optic nerve fibers necessary for vision.
glaucoma does affect reading. Why? First, while glaucoma does affect peripheral vision, it also affects central vision. Glaucoma patients with moderate or severe disease often describe looking through a fog which extends into their central vision.
Glaucoma is a disease where the optic nerve gets damaged and the main risk factor is elevated eye pressure (also called intraocular pressure, IOP). The only treatment is to lower the IOP.
Glaucoma Research Foundation (GRF) is pleased to announce the addition of Meredith L. Gale as the organization's new Director of Development. Meredith joins the GRF team to manage donor stewardship programs as well as major and planned giving strategies. Additionally, she will coordinate the GRF Ambassadors program, a national leadership group of glaucoma doctors dedicated to improving access to patient education.
Glaucoma Research Foundation, a national non-profit organization dedicated to finding a cure for glaucoma, today announced a team of neuroscience researchers, led by Adriana Di Polo, PhD, at University of Montreal, have made a major breakthrough in the treatment of glaucoma. The research, which was made possible by a Glaucoma Research Foundation Shaffer Grant, could also be applicable to other neurodegenerative diseases, including Alzheimer's disease.
If you have glaucoma, you're wondering: What will my new ophthalmologist need to hit the ground running and manage my disease? In my experience, to make a smooth transition to optimal care, the most important thing you can do is create a personal Glaucoma Data Portfolio
GRF has announced the celebration of its 40th anniversary year, the board approval of its new strategic plan, and an expanded capital campaign designed to accelerate research towards a cure.
Glaucoma Research Foundation (GRF) announced today $720,000 in annual research grants to support 12 investigators at prestigious universities across the United States.
The Shaffer Prize, presented annually by Glaucoma Research Foundation, recognizes a researcher whose project best exemplifies the pursuit of innovative ideas in the quest to better understand glaucoma.
The Catalyst Award, Glaucoma Research Foundation's highest honor, will be presented to Thomas W. Burns, President and CEO of Glaukos Corporation (Laguna Hills, CA), in recognition of his remarkable leadership and commitment to the development of innovative glaucoma treatments.
Glaucoma Research Foundation will host the 7th Annual Glaucoma 360 from February 8th to February 10th in San Francisco. This signature three-day event highlights innovation in glaucoma to ensure patients have access to the latest and most effective treatment options.
Dr. Jeff Goldberg: I really want to thank the Glaucoma Research Foundation. Obviously, what we’re going to talk about today would not come to fruition without the support of the Glaucoma Research Foundation and of course, all of their supporters.
People with obstructive sleep apnea syndrome (OSAS), a disorder characterized by repetitive episodes of paused and shallow breathing during sleep, are approximately ten times more likely to develop glaucoma.
At present, the only FDA approved method of treating glaucoma is to lower eye pressure; this slows the progression of glaucomatous optic nerve damage but does not completely halt it, and certainly does not regenerate damaged nerve tissue.
Research scientists interested in applying for a 1-year, $40,000 Shaffer Grant should visit the Glaucoma Research Foundation website.
Traditional eye drops, while the go-to medication option for glaucoma patients, still have lots of room for improvement. Dosing regimens can be difficult to manage or remember, irritation or redness can occur, and much of the medication gets blinked away before reaching the eye. Because of these challenges, researchers are working to make taking glaucoma medication easier.
The 4-star rating is Charity Navigator’s highest rating, indicating that “Glaucoma Research Foundation exceeds industry standards and outperforms most charities in its Cause.”
Showing results
1–50 of 79
RSS Feeds by Section